Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

¹⁷⁷Lu - PSMA-617 has been approved for treatment of mCRPC based on positive phase III studies. While this treatment is tolerable and effective, biomarkers are necessary to determine which patients will benefit. In the future, radioligand treatments will likely be utilized in earlier lines of therapy and potentially in combination with other prostate cancer treatments.